FINANCIAL TIMES | There are promising treatments against drug-resistant bacteria in the pipeline despite an on-going troubling lack of financial incentives to repair the broken market for antibiotics. The support for new urgently needed products is coming from non-profit organizations– philanthropic and government-backed organizations – that are funding small biotech companies and research teams. CARB-X has the largest portfolio, with 49 projects progressing, and there are plenty of exciting and promising scientific approaches in development. The launch of the AMR Action Fund in July will support later development of 15 – 20 new antibiotics and aim to bring two to four to market.  Despite this progress, more is needed to sustain the development of innovative products that are needed to address the drug-resistance crisis.